NDA 020771 · Upjohn
Detrol
Tolterodine Tartrate · Oral
NovelLast checked: Nov 19, 2026Latest source record: Jul 28, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Mar 25, 1998
Approved uses
2
Original approval plus efficacy supplements
Registered trials
110
33 Phase 3, 3 recruiting
FAERS reports
8,980
5,709 serious, 551 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 15, 2023.
INDICATIONS AND USAGE DETROL Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 6, 2001 Supplement 4 · Efficacy LabelReviewLetter
- Mar 25, 1998 Original approval · Type 1 - New Molecular Entity ReviewLabelLetter
2 products under this application
- DETROL · TOLTERODINE TARTRATE 1MG · TABLET, ORAL · Prescription · TE AB
- DETROL · TOLTERODINE TARTRATE 2MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tolterodine" as an intervention, any sponsor and status, largest first.
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00688688 · 2,792 participants · Start Apr 25, 2008 · Primary completion May 6, 2010
Drug: Mirabegron; Tolterodine and 2 more · For: Urinary Bladder, Overactive
Sites: Homewood, Alabama; Huntsville, Alabama; Mobile, Alabama · 308 sites in all
- Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00611026 · 2,417 participants · Start Feb 2008 · Primary completion Oct 2009
Drug: Tolterodine ER; Placebo and 1 more · For: Overactive Bladder
Sites: Enterprise, Alabama; Mobile, Alabama; Montgomery, Alabama · 227 sites in all
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00689104 · 2,336 participants · Start Apr 28, 2008 · Primary completion Mar 24, 2009
Drug: Mirabegron; Tolterodine and 2 more · For: Urinary Bladder, Overactive
Sites: Auchenflower, Australia; Clayton, Australia; Kogarah, Australia · 218 sites in all
- Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00444925 · 1,712 participants · Start Apr 2007 · Primary completion Jul 2008
Drug: fesoterodine fumarate; placebo and 1 more · For: Overactive Bladder
Sites: Homewood, Alabama; Huntsville, Alabama; Mobile, Alabama · 178 sites in all
- A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)Pivotal-lookingCompleted
Urovant Sciences GmbHIndustry
NCT03492281 · 1,530 participants · Start Mar 26, 2018 · Primary completion Jan 10, 2019
Drug: vibegron; Vibegron placebo and 2 more · For: Overactive Bladder
Sites: Birmingham, Alabama; Gulf Shores, Alabama; Huntsville, Alabama · 215 sites in all
- A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01314872 · 1,395 participants · Start Mar 31, 2011 · Primary completion Oct 22, 2012
Drug: Vibegron; Tolterodine ER and 2 more · For: Urinary Bladder, Overactive
- Solifenacin Succinate Versus Tolterodine 4mg Once DailyPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00802373 · 1,355 participants · Start Jul 2003 · Primary completion Oct 2004
Drug: Solifenacin succinate; Tolterodine · For: Urinary Bladder, Overactive
Sites: Minsk, Belarus; Antwerp, Belgium; Brussels, Belgium · 95 sites in all
- A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive BladderPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00966004 · 1,139 participants · Start Jul 24, 2009 · Primary completion Feb 15, 2010
Drug: YM178; Placebo and 1 more · For: Urinary Bladder, Overactive
Sites: Chūbu, Japan; Kantou, Japan; Kinki, Japan · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective882
- fatigue586
- fall580
- nausea532
- dizziness466
- headache449
- asthenia437
- diarrhoea416
- pain401
- urinary tract infection377
- dyspnoea375
- constipation322
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 383 |
| 2005 | 519 |
| 2006 | 455 |
| 2007 | 369 |
| 2008 | 408 |
| 2009 | 420 |
| 2010 | 600 |
| 2011 | 474 |
| 2012 | 537 |
| 2013 | 294 |
| 2014 | 498 |
| 2015 | 465 |
| 2016 | 488 |
| 2017 | 454 |
| 2018 | 446 |
| 2019 | 481 |
| 2020 | 373 |
| 2021 | 267 |
| 2022 | 276 |
| 2023 | 184 |
| 2024 | 249 |
| 2025 | 202 |
| 2026 | 136 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Detrol (Tolterodine Tartrate)
2024 spending
$84K
Beneficiaries
35
94 claims
Per beneficiary
$2,389
$7.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $233,230 |
| 2021 | $200,690 |
| 2022 | $83,300 |
| 2023 | $98,513 |
| 2024 | $83,602 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nocturnal enuresis.
Kiddoo D · BMJ Clin Evid 2011 · Systematic Review
- Nocturnal enuresis.
Kiddoo D · BMJ Clin Evid 2007 · Systematic Review
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.
He W, Zhang Y, Huang G, et al. · Low Urin Tract Symptoms 2023 · Systematic Review, Network Meta-Analysis
- Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, et al. · Int Braz J Urol 2023 · Systematic Review, Network Meta-Analysis
- International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D, Frankel J, Varano S, et al. · J Urol 2020 · Clinical Trial, Phase III, Multicenter Study
- Transdermal oxybutynin: for overactive bladder.
Bang LM, Easthope SE, Perry CM · Drugs Aging 2003 · Clinical Trial, Comparative Study
Sponsor: Upjohn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.